Related Experiment Video
Updated: Jun 24, 2026
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell
Gullu Gorgun1, Alan G Ramsay, Tobias A W Holderried
1Department of Medical Oncology, The Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Abstract:
Preclinical animal models have largely ignored the immune-suppressive mechanisms that are important in human cancers. The identification and use of such models should allow better predictions of successful human responses to immunotherapy. As a model for changes induced in nonmalignant cells by cancer, we examined T-cell function in the chronic lymphocytic leukemia (CLL) Emu-TCL1 transgenic mouse model. With development of leukemia, Emu-TCL1 transgenic mice developed functional T-cell defects and alteration of gene and protein expression closely resembling changes seen in CLL human patients. Furthermore, infusion of CLL cells into young Emu-TCL1 mice induced defects comparable to those seen in mice with developed leukemia, demonstrating a causal relationship between leukemia and the T-cell defects. Altered pathways involved genes regulating actin remodeling, and T cells exhibited dysfunctional immunological synapse formation and T-cell signaling, which was reversed by the immunomodulatory drug lenalidomide. These results further demonstrate the utility of this animal model of CLL and define a versatile model to investigate both the molecular mechanisms of cancer-induced immune suppression and immunotherapeutic repair strategies.
Insights
This study reveals that the Emu-TCL1 mouse model mimics human chronic lymphocytic leukemia (CLL) T-cell defects. These findings highlight a new model for understanding cancer-induced immune suppression and testing immunotherapies.
Area of Science:
- Immunology
- Oncology
- Translational Medicine
Background:
- Preclinical cancer models often overlook immune suppression crucial in human cancers.
- Effective immunotherapy prediction requires models that replicate human cancer immune environments.
Purpose of the Study:
- To investigate T-cell function in the Emu-TCL1 transgenic mouse model of chronic lymphocytic leukemia (CLL).
- To establish a causal link between leukemia and T-cell dysfunction.
- To evaluate lenalidomide's potential to reverse these defects.
Main Methods:
- Examined T-cell function in Emu-TCL1 transgenic mice during leukemia development.
- Infused CLL cells into young Emu-TCL1 mice to assess causality.
- Analyzed gene and protein expression, immunological synapse formation, and T-cell signaling.
- Assessed the effect of lenalidomide on T-cell function.
Main Results:
- Emu-TCL1 mice exhibited T-cell defects and altered gene/protein expression mirroring human CLL.
- Leukemia development causally induced T-cell defects, evidenced by infusion experiments.
- Altered pathways included actin remodeling genes, leading to impaired T-cell synapse formation and signaling.
- Lenalidomide reversed these T-cell defects.
Conclusions:
- The Emu-TCL1 mouse is a valuable preclinical model for CLL, accurately reflecting human T-cell dysfunction.
- This model facilitates research into cancer-induced immune suppression mechanisms.
- It serves as a platform for developing and testing novel immunotherapeutic strategies.
